Out-of-Pocket Costs for Patients Using Generic Versus Brand-Name Prescription Medications

Overview

This analysis reveals that generic medications account for 51.91% of prescriptions filled, with mean annual out-of-pocket spending of $51 for generics compared to $41 for brand-name drugs. Nationally, out-of-pocket spending was estimated at $16.8 billion for generics and $13.7 billion for brand-name medications.

Background

Generic medications represent a significant portion of prescriptions in the U.S., typically resulting in lower out-of-pocket costs for patients. This study provides insights into the distribution of out-of-pocket spending between these two categories of medications.

Data Highlights

Key Findings

• 51.91% of individuals filled generic medications, while 15.81% filled brand-name medications.
• The mean number of generic medications filled was 1.81, compared to 0.22 for brand-name drugs.
• Among those using generics, 14.29% spent more than $100 annually, compared to 6.11% for brand-name medications.
• Medicare enrollees filled an average of 4.1 generic and 0.4 brand-name medications, with out-of-pocket spending of $129 and $143, respectively.
• Medicaid beneficiaries had the lowest mean annual out-of-pocket spending: $6 for generics and $3 for brand-name medications.

Clinical Implications

Healthcare professionals should be aware of the financial burden associated with both generic and brand-name medications, particularly for patients with varying insurance statuses. This understanding can inform discussions with patients regarding medication choices and potential costs.

Conclusion

The findings indicate the distribution of out-of-pocket spending between generic and brand-name medications.

Related Resources & Content

1. Ophthalmology Management, 2015 -- How to Ensure a Drug is Dispensed as Written
2. Ophthalmology Management, 2011 -- Generics in Practice: Physician Perspectives
3. Ophthalmology Management, 2016 -- Generics can help with adherence ...
4. FDA -- Evaluation of Therapeutic Equivalence
5. JAMA Health Forum, 2026 -- Changes in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps
6. Ophthalmology Management — Branded Drugs: Accept No Substitute?
7. Evaluation of Therapeutic Equivalence | FDA
8. Changes in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps | Health Policy | JAMA Health Forum | JAMA Network
9. March 2026 Report to the Congress: Medicare Payment Policy